Headlines about Amarin (NASDAQ:AMRN) have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amarin earned a news impact score of 0.14 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 47.9779914525964 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipids and Inflammatory Markers in Patients With Persistent High Triglycerides and Elevated High-Sensitivity C-Reactive Protein (hsCRP) (finance.yahoo.com)
- Real-World Data Supports Association Between Elevated Triglyceride Levels and Increased Cardiovascular Events and Healthcare Costs (finance.yahoo.com)
- Amarin Co. plc (AMRN) Sees Significant Growth in Short Interest (americanbankingnews.com)
- Cramer’s lightning round: I screwed up on Apache and won’t stop you from selling (finance.yahoo.com)
- Cramer's lightning round: I screwed up on Apache and won'… (finance.yahoo.com)
Several research firms have recently commented on AMRN. Cantor Fitzgerald set a $10.00 price target on shares of Amarin and gave the stock a “buy” rating in a research report on Monday. Zacks Investment Research lowered shares of Amarin from a “hold” rating to a “sell” rating in a research report on Friday, March 2nd. HC Wainwright reiterated a “buy” rating on shares of Amarin in a research report on Thursday, March 1st. Finally, BidaskClub downgraded shares of Amarin from a “sell” rating to a “strong sell” rating in a report on Friday, March 2nd. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $7.75.
Amarin (NASDAQ:AMRN) last released its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). The company had revenue of $53.87 million during the quarter, compared to analysts’ expectations of $52.73 million. During the same quarter in the prior year, the company earned ($0.10) EPS. The business’s revenue was up 39.2% compared to the same quarter last year. sell-side analysts forecast that Amarin will post -0.33 earnings per share for the current fiscal year.
In related news, insider Steven B. Ketchum sold 128,257 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $4.25, for a total value of $545,092.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Joseph T. Kennedy sold 44,857 shares of the firm’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $3.73, for a total value of $167,316.61. The disclosure for this sale can be found here. In the last quarter, insiders have sold 426,720 shares of company stock worth $1,814,296. Corporate insiders own 3.72% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Amarin (NASDAQ:AMRN) Receiving Somewhat Favorable News Coverage, Analysis Finds” was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://baseballnewssource.com/2018/03/14/amarin-amrn-receiving-somewhat-favorable-news-coverage-study-shows/1971831.html.
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.